Zacks.com on MSN17h
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...
Bellevue startup, armed with $320 million, undertakes ambitious project to aid medical research
Regeneron, San Diego-based biotech company Illumina and 17 health systems invested in the $320 million round. Regeneron ...
CRISPR Therapeutics AG (CRSP): Among Cathie Wood’s Top Stock Picks for 2025
CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...
STAT1d
The CRISPR companies are not OK
Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...
STAT4d
Pfizer’s Braftovi extends survival in colorectal cancer
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.